Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering
Revelation Biosciences, Inc.
Revelation Biosciences Inc. (REVB)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Sabby Capital Hal Mintz | 207,051 | $294,012 | 0.34% | |
| 2. | Armistice Capital Steven Boyd | 80,000 | $113,600 | 0% | |
| 3. | 31,798 | $321 | +165% | 0% | |
| 4. | Sabby Capital Hal Mintz | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.16 | 25,000 | $29,000.00 | 64,848 | 2023-04-18 | Filing | |
| $1.16 | 26,500 | $30,740.00 | 39,848 | 2023-04-17 | Filing | |
| $1.60 | 20,000 | $32,000.00 | 467,156 | 2022-02-25 | Filing | |
| $2.55 | 30,000 | $76,599.00 | 447,156 | 2022-02-09 | Filing | |
| $2.54 | 1,000 | $2,540.00 | 417,156 | 2022-02-08 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.52 | 27,771 | $14,438.14 | 0 | 2023-12-08 | Filing | |
| $0.65 | 1,845 | $1,199.43 | 27,771 | 2023-10-16 | Filing | |
| $0.66 | 10,957 | $7,242.58 | 42,096 | 2023-10-16 | Filing | |
| $0.69 | 1,429 | $986.01 | 42,096 | 2023-09-28 | Filing | |
| $0.74 | 4,000 | $2,960.00 | 39,348 | 2023-09-18 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 77,272 | $109,726 | 0% | |
| 2. | 14,764 | $20,965 | 0% | |
| 3. | 338,110 | $3,913 | 0% | |
| 4. | 247,434 | $3,093 | 0% | |
| 5. | 99,450 | $1,293 | 0% |
News See All
5 Cheap Penny Stocks to Buy According to Analysts
Workforce solutions company GEE Group Inc (NYSE:JOB) ranks fifth in our list of the cheap penny stocks to buy according to Wall Street analysts.
Hedge Fund and Insider Trading News: Neil Woodford, Cathie Wood, BFAM Partners, Tiger Global Management, L1 Capital Long Short Fund, Three Arrows Capital (3AC), Revelation Biosciences Inc (REVB), Ambrx Biopharma Inc. (AMAM), and More
Investors trapped in Neil Woodford’s failed equity fund are set to get up to £235 million ($292 million) in compensation after a regulatory probe found its administrator mismanaged liquidity in the...